Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 126 publications
Targeting PI3K decreases trogocytosis-mediated CAR T cell fratricide.
Journal: Leukemia
Published: May 08, 2026
Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies.
Journal: Future oncology (London, England)
Published: April 23, 2026
Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma.
Journal: Blood cancer journal
Published: April 17, 2026
The Association of Age and Frailty With Adverse Events for Bortezomib and Carfilzomib: A Population-Based Analysis.
Journal: American journal of hematology
Published: February 13, 2026
Changes in patient-reported distress and symptom burden during talquetamab therapy in multiple myeloma.
Journal: British journal of haematology
Published: December 10, 2025
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.
Journal: Blood cancer journal
Published: December 04, 2025
Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant-Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal Antibody-Based Regimens: Is 24 Weeks Optimal?
Journal: American journal of hematology
Published: November 08, 2025
Stem cell boost for immune effector cell associated hematotoxicity in multiple myeloma: minimizing long-term complications and expanding post CAR T-cell therapy relapse options.
Journal: Expert review of hematology
Published: October 04, 2025
Last Updated: 09/26/2026